{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T04:09:43Z","timestamp":1789704583578,"version":"4.0.1"},"reference-count":194,"publisher":"Bentham Science Publishers Ltd.","issue":"9","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CDT"],"published-print":{"date-parts":[[2026,8]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction:<\/jats:title>\n                    <jats:p>Rheumatoid Arthritis (RA) is a chronic systemic autoimmune disease\ncharacterized by persistent joint inflammation. Genetically predisposed conditions like Human\nLeukocyte Antigen DR1 (HLA-DR1) and Human Leukocyte Antigen DR4 (HLA-DR4), coupled\nwith environmental insults like infection, smoking, diet, and stress, are etiological factors in immune\ndysregulation. It results in the overproduction of pro-inflammatory cytokines and autoantibodies,\nultimately causing synovial inflammation and joint destruction. The objective of this review\nis to highlight the latest developments in RA management through new drug formulations,\ntargeted biologics, and novel Drug Delivery Systems (DDS).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>A systematic literature search of scientific articles, registered trials, and published patents\nrelated to RA treatments was conducted. This review specifically focused on biologic Disease-\nModifying Anti-Rheumatic Drugs (biologic DMARDs), small-molecule inhibitors, biomarker-\ndirected personalized medicine, and DDS technologies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Biologic DMARDs, like Tumor Necrosis Factor (TNF) and interleukin inhibitors, have\ncompletely transformed the management of RA by targeting disease mechanisms. Small-molecule\ninhibitors became available with a similar efficacy to orally bioavailable forms. ADI has improved\ndrug specificity, increased therapeutic efficacy, and decreased systemic toxicity. Biomarker-\ndirected therapy has promise for improving treatment benefit.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion:<\/jats:title>\n                    <jats:p>Current RA therapies highlight a shift toward biologics, personalized medicine, and\nadvanced drug-delivery systems, enabling targeted action, reduced toxicity, and improved longterm\ndisease management outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Biologic drugs, small-molecule inhibitors, and DDS technology are revolutionizing\ntreatment for RA. These strategies increase efficacy, decrease side effects, and provide cost-effective,\nsustained therapy. The intersection of personalized medicine and advanced drug delivery is a\nfuture solution for enhancing patient outcomes and quality of life.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2174\/0113894501396008251028055819","type":"journal-article","created":{"date-parts":[[2026,3,15]],"date-time":"2026-03-15T07:50:59Z","timestamp":1773561059000},"page":"623-642","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Rheumatoid Arthritis Management: Emerging Drug Therapies and Innovations"],"prefix":"10.2174","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-7311-323X","authenticated-orcid":true,"family":"Dushyant","sequence":"first","affiliation":[{"name":"Global Research Institute of Pharmacy, Radaur, Yamuna Nagar, Haryana, 135133, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-6506-9234","authenticated-orcid":true,"given":"Smita","family":"Narwal","sequence":"additional","affiliation":[{"name":"Global Research Institute of Pharmacy, Radaur, Yamuna Nagar, Haryana, 135133, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-7938-1546","authenticated-orcid":true,"given":"Gurvirender","family":"Singh","sequence":"additional","affiliation":[{"name":"Institute ofPharmaceutical Sciences, Kurukshetra University, Kurukshetra, Haryana, 136119, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-0090-2241","authenticated-orcid":true,"given":"Tavleen","family":"Kaur","sequence":"additional","affiliation":[{"name":"Global Research Institute of Pharmacy, Radaur, Yamuna Nagar, Haryana, 135133, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7574-2971","authenticated-orcid":true,"given":"Ashwani K.","family":"Dhingra","sequence":"additional","affiliation":[{"name":"Global Research Institute of Pharmacy, Radaur, Yamuna Nagar, Haryana, 135133, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nisha","family":"Grewal","sequence":"additional","affiliation":[{"name":"Global Research Institute of Pharmacy, Radaur, Yamuna Nagar, Haryana, 135133, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geeta","family":"Jangra","sequence":"additional","affiliation":[{"name":"Institute ofPharmaceutical Sciences, Kurukshetra University, Kurukshetra, Haryana, 136119, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/j.medcli.2023.07.014","volume":"161","author":"D\u00edaz-Gonz\u00e1lez F","year":"2023","unstructured":"D\u00edaz-Gonz\u00e1lez F; Hern\u00e1ndez-Hern\u00e1ndez MV; Rheumatoid arthritis. Med Clin  2023,161(12),533-542","journal-title":"Med Clin"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"2019","DOI":"10.1016\/S0140-6736(23)01525-8","volume":"402","author":"Di Matteo A","year":"2023","unstructured":"Di Matteo A; Bathon JM; Emery P; Rheumatoid arthritis. Lancet  2023,402(10416),2019-2033","journal-title":"Lancet"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/j.rdc.2022.02.010","volume":"48","author":"Cush J.J.","year":"2022","unstructured":"Cush J.J.; Rheumatoid arthritis. Rheum Dis Clin North Am  2022,48(2),537-547","journal-title":"Rheum Dis Clin North Am"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"2857","DOI":"10.3390\/cells10112857","volume":"10","author":"Radu AF","year":"2021","unstructured":"Radu AF; Bungau SG; Management of rheumatoid arthritis: An overview. Cells  2021,10(11),2857","journal-title":"Cells"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"905","DOI":"10.3390\/ijms23020905","volume":"23","author":"g S","year":"2022","unstructured":"g S; Kwon EJ; Lee JJ; Rheumatoid Arthritis: Pathogenic roles of diverse immune cells. Int J Mol Sci  2022,23(2),905","journal-title":"Int J Mol Sci"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1001\/jama.2018.13103","volume":"320","author":"Aletaha D","year":"2018","unstructured":"Aletaha D; Smolen JS; Diagnosis and management of rheumatoid arthritis: A review. JAMA  2018,320(13),1360-1372","journal-title":"JAMA"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1038\/s41584-023-00992-8","volume":"19","author":"van Sleen Y.","year":"2023","unstructured":"van Sleen Y.; van der Geest K.S.M.; Huckriede A.L.W.; van Baarle D.; Brouwer E.; Effect of DMARDs on the immunogenicity of vaccines. Nat Rev Rheumatol  2023,19(9),560-575","journal-title":"Nat Rev Rheumatol"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"2338","DOI":"10.1016\/S0140-6736(17)31491-5","volume":"389","author":"Burmester GR","year":"2017","unstructured":"Burmester GR; Pope JE; Treatment strategies in rheumatoid arthritis. Lancet  2017,389(10086),2338-2348","journal-title":"Lancet"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1002\/acr.24596","volume":"73","author":"Fraenkel L","year":"2021","unstructured":"Fraenkel L; Bathon JM; England BR; St Clair EW; Arayssi T; Carandang K; Deane KD; Genovese M; Huston KK; Kerr G; Kremer J; Nakamura MC; Russell LA; Singh JA; Smith BJ; Sparks JA; Venkatachalam S; Weinblatt ME; Al-Gibbawi M; Baker JF; Barbour KE; Barton JL; Cappelli L; Chamseddine F; George M; Johnson SR; Kahale L; Karam BS; Khamis AM; Navarro-Mill\u00e1n I; Mirza R; Schwab P; Singh N; Turgunbaev M; Turner AS; Yaacoub S; Akl EA; 2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res  2021,73(7),924-939","journal-title":"Arthritis Care Res"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1016\/j.rdc.2022.03.005","volume":"48","author":"Singh J.A.","year":"2022","unstructured":"Singh J.A.; Treatment guidelines in rheumatoid arthritis. Rheum Dis Clin North Am  2022,48(3),679-689","journal-title":"Rheum Dis Clin North Am"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.3390\/biom10111479","volume":"10","author":"Zaragoza-Garc\u00eda O","year":"2020","unstructured":"Zaragoza-Garc\u00eda O; Castro-Alarc\u00f3n N; P\u00e9rez-Rubio G; Guzm\u00e1n-Guzm\u00e1n IP; DMARDs-gut microbiota feedback: Implications in the response to therapy. Biomolecules  2020,10(11),1479","journal-title":"Biomolecules"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"e003487","DOI":"10.1136\/rmdopen-2023-003487","volume":"9","author":"Yuan H.","year":"2023","unstructured":"Yuan H.; Cui S.; Yang L.; Cui J.; Wang X.; Ding M.; Jin L.; Wang Y.; Chang F.; Jin H.; Ma J.; Shi M.; Liu A.; Efficacy of non-conventional synthetic DMARDs for patients with rheumatoid arthritis-associated interstitial lung disease: A systematic review and meta-analysis. RMD Open  2023,9(4),e003487","journal-title":"RMD Open"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.1016\/j.immuni.2022.11.009","volume":"55","author":"Alivernini S","year":"2022","unstructured":"Alivernini S; Firestein GS; McInnes IB; The pathogenesis of rheumatoid arthritis. Immunity  2022,55(12),2255-2270","journal-title":"Immunity"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"110655","DOI":"10.1016\/j.intimp.2023.110655","volume":"122","author":"Guo H.","year":"2023","unstructured":"Guo H.; Li L.; Liu B.; Lu P.; Cao Z.; Ji X.; Li L.; Ouyang G.; Nie Z.; Lyu A.; Lu C.; Inappropriate treatment response to DMARDs: A pathway to difficult-to-treat rheumatoid arthritis. Int Immunopharmacol  2023,122,110655","journal-title":"Int Immunopharmacol"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1007\/s11010-022-04492-3","volume":"478","author":"Prasad P.","year":"2023","unstructured":"Prasad P.; Verma S.; Surbhi ; Ganguly N.K.; Chaturvedi V.; Mittal S.A.; Rheumatoid arthritis: Advances in treatment strategies. Mol Cell Biochem  2023,478(1),69-88","journal-title":"Mol Cell Biochem"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"2834","DOI":"10.26355\/eurrev_202104_25536","volume":"25","author":"Mu\u00f1oz-Mart\u00ednez C.","year":"2021","unstructured":"Mu\u00f1oz-Mart\u00ednez C.; Segura-Puertas M.; G\u00f3mez-Moreno G.; Disease-Modifying Antirheumatic Drugs (DMARDs) and drug interactions in dentistry. Eur Rev Med Pharmacol Sci  2021,25(7),2834-2842","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.1016\/S0140-6736(16)30173-8","volume":"388","author":"Smolen J.S.","year":"2016","unstructured":"Smolen J.S.; Aletaha D.; McInnes I.B.; Rheumatoid arthritis. Lancet  2016,388(10055),2023-2038","journal-title":"Lancet"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"686155","DOI":"10.3389\/fimmu.2021.686155","volume":"12","author":"Huang J.","year":"2021","unstructured":"Huang J.; Fu X.; Chen X.; Li Z.; Huang Y.; Liang C.; Promising therapeutic targets for treatment of rheumatoid arthritis. Front Immunol  2021,12,686155","journal-title":"Front Immunol"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1056\/NEJMra2103726","volume":"388","author":"Gravallese E.M.","year":"2023","unstructured":"Gravallese E.M.; Firestein G.S.; Rheumatoid arthritis \u2014 Common origins, divergent mechanisms. N Engl J Med  2023,388(6),529-542","journal-title":"N Engl J Med"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.3390\/nu12051456","volume":"12","author":"Gioia C.","year":"2020","unstructured":"Gioia C.; Lucchino B.; Tarsitano M.G.; Iannuccelli C.; Di Franco M.; Dietary habits and nutrition in rheumatoid arthritis: Can diet influence disease development and clinical manifestations? Nutrients  2020,12(5),1456","journal-title":"Nutrients"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"102741","DOI":"10.1016\/j.autrev.2020.102741","volume":"20","author":"Ilchovska D.D.","year":"2021","unstructured":"Ilchovska D.D.; Barrow D.M.; An Overview of the NF-kB mechanism of pathophysiology in rheumatoid arthritis, investigation of the NF-kB ligand RANKL and related nutritional interventions. Autoimmun Rev  2021,20(2),102741","journal-title":"Autoimmun Rev"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1136\/annrheumdis-2020-217344","volume":"80","author":"Nagy G.","year":"2021","unstructured":"Nagy G.; Roodenrijs N.M.T.; Welsing P.M.J.; Kedves M.; Hamar A.; van der Goes M.C.; Kent A.; Bakkers M.; Blaas E.; Senolt L.; Szekanecz Z.; Choy E.; Dougados M.; Jacobs J.W.G.; Geenen R.; Bijlsma H.W.J.; Zink A.; Aletaha D.; Schoneveld L.; van Riel P.; Gutermann L.; Prior Y.; Nikiphorou E.; Ferraccioli G.; Schett G.; Hyrich K.L.; Mueller-Ladner U.; Buch M.H.; McInnes I.B.; van der Heijde D.; van Laar J.M.; EULAR definition of difficult-to-treat rheumatoid arthritis. Ann Rheum Dis  2021,80(1),31-35","journal-title":"Ann Rheum Dis"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"477","DOI":"10.3238\/arztebl.2013.0477","volume":"110","author":"Schneider M.","year":"2013","unstructured":"Schneider M.; Kr\u00fcger K.; Rheumatoid arthritis-early diagnosis and disease management. Dtsch Arztebl Int  2013,110(27-28),477-484","journal-title":"Dtsch Arztebl Int"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1097\/CRD.0000000000000486","volume":"32","author":"Sanghavi N","year":"2024","unstructured":"Sanghavi N; Ingrassia JP; Korem S; Ash J; Pan S; Wasserman A; Cardiovascular manifestations in rheumatoid arthritis. Cardiol Rev  2024,32(2),146-152","journal-title":"Cardiol Rev"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1080\/25785826.2023.2235734","volume":"47","author":"Yamada S.","year":"2024","unstructured":"Yamada S.; Nagafuchi Y.; Fujio K.; Pathophysiology and stratification of treatment-resistant rheumatoid arthritis. Immunol Med  2024,47(1),12-23","journal-title":"Immunol Med"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"e25019","DOI":"10.1097\/MD.0000000000025019","volume":"100","author":"Wen Z.","year":"2021","unstructured":"Wen Z.; Chai Y.; Effectiveness of resistance exercises in the treatment of rheumatoid arthritis. Medicine  2021,100(13),e25019","journal-title":"Medicine"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"103337","DOI":"10.1016\/j.autrev.2023.103337","volume":"22","author":"Bansal N.","year":"2023","unstructured":"Bansal N.; Pasricha C.; Kumari P.; Jangra S.; Kaur R.; Singh R.; A comprehensive overview of juvenile idiopathic arthritis: From pathophysiology to management. Autoimmun Rev  2023,22(7),103337","journal-title":"Autoimmun Rev"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1080\/08916934.2021.1963959","volume":"54","author":"Kaur G.","year":"2021","unstructured":"Kaur G.; Sharma A.; Bhatnagar A.; Role of oxidative stress in pathophysiology of rheumatoid arthritis: Insights into NRF2-KEAP1 signalling. Autoimmunity  2021,54(7),385-397","journal-title":"Autoimmunity"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1080\/17476348.2022.2089116","volume":"16","author":"Diesler R.","year":"2022","unstructured":"Diesler R.; Cottin V.; Pulmonary fibrosis associated with rheumatoid arthritis: From pathophysiology to treatment strategies. Expert Rev Respir Med  2022,16(5),541-553","journal-title":"Expert Rev Respir Med"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"6619","DOI":"10.1007\/s11033-021-06672-8","volume":"48","author":"Moreira F.R.C.","year":"2021","unstructured":"Moreira F.R.C.; de Oliveira T.A.; Ramos N.E.; Abreu M.A.D.; Sim\u00f5es e Silva A.C.; Silva A.C.; The role of renin angiotensin system in the pathophysiology of rheumatoid arthritis. Mol Biol Rep  2021,48(9),6619-6629","journal-title":"Mol Biol Rep"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1007\/s10787-024-01445-8","volume":"32","author":"Kaur C.","year":"2024","unstructured":"Kaur C.; Mishra Y.; Kumar R.; Singh G.; Singh S.; Mishra V.; Tambuwala M.M.; Pathophysiology, diagnosis, and herbal medicine-based therapeutic implication of rheumatoid arthritis: An overview. Inflammopharmacology  2024,32(3),1705-1720","journal-title":"Inflammopharmacology"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1186\/s13073-022-01081-3","volume":"14","author":"Armaka M.","year":"2022","unstructured":"Armaka M.; Konstantopoulos D.; Tzaferis C.; Lavigne M.D.; Sakkou M.; Liakos A.; Sfikakis P.P.; Dimopoulos M.A.; Fousteri M.; Kollias G.; Single-cell multimodal analysis identifies common regulatory programs in synovial fibroblasts of rheumatoid arthritis patients and modeled TNF-driven arthritis. Genome Med  2022,14(1),78","journal-title":"Genome Med"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"790122","DOI":"10.3389\/fimmu.2021.790122","volume":"12","author":"Zhao J.","year":"2021","unstructured":"Zhao J.; Guo S.; Schrodi S.J.; He D.; Molecular and cellular heterogeneity in rheumatoid arthritis: Mechanisms and clinical implications. Front Immunol  2021,12,790122","journal-title":"Front Immunol"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"107392","DOI":"10.1016\/j.intimp.2021.107392","volume":"93","author":"Wu Z.","year":"2021","unstructured":"Wu Z.; Ma D.; Yang H.; Gao J.; Zhang G.; Xu K.; Zhang L.; Fibroblast-like synoviocytes in rheumatoid arthritis: Surface markers and phenotypes. Int Immunopharmacol  2021,93,107392","journal-title":"Int Immunopharmacol"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"114368","DOI":"10.1016\/j.jep.2021.114368","volume":"279","author":"Wang Y.","year":"2021","unstructured":"Wang Y.; Chen S.; Du K.; Liang C.; Wang S.; Owusu Boadi E.; Li J.; Pang X.; He J.; Chang Y.; Traditional herbal medicine: Therapeutic potential in rheumatoid arthritis. J Ethnopharmacol  2021,279,114368","journal-title":"J Ethnopharmacol"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1038\/s41584-020-0419-z","volume":"16","author":"Choy E.H.","year":"2020","unstructured":"Choy E.H.; De Benedetti F.; Takeuchi T.; Hashizume M.; John M.R.; Kishimoto T.; Translating IL-6 biology into effective treatments. Nat Rev Rheumatol  2020,16(6),335-345","journal-title":"Nat Rev Rheumatol"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"1878","DOI":"10.1016\/S0140-6736(23)00457-9","volume":"401","author":"Conrad N.","year":"2023","unstructured":"Conrad N.; Misra S.; Verbakel J.Y.; Verbeke G.; Molenberghs G.; Taylor P.N.; Mason J.; Sattar N.; McMurray J.J.V.; McInnes I.B.; Khunti K.; Cambridge G.; Incidence, prevalence, and co-occurrence of autoimmune disorders over time and by age, sex, and socioeconomic status: A population-based cohort study of 22 million individuals in the UK. Lancet  2023,401(10391),1878-1890","journal-title":"Lancet"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"e594","DOI":"10.1016\/S2665-9913(23)00211-4","volume":"5","author":"Black R.J.","year":"2023","unstructured":"Black R.J.; Cross M.; Haile L.M.; Culbreth G.T.; Steinmetz J.D.; Hagins H.; Kopec J.A.; Brooks P.M.; Woolf A.D.; Ong K.L.; Kopansky-Giles D.R.; Dreinhoefer K.E.; Betteridge N.; Aali A.; Abbasifard M.; Abbasi-Kangevari M.; Abdurehman A.M.; Abedi A.; Abidi H.; Aboagye R.G.; Abolhassani H.; Abu-Gharbieh E.; Abu-Zaid A.; Adamu K.; Addo I.Y.; Adesina M.A.; Adnani Q.E.S.; Afzal M.S.; Ahmed A.; Aithala J.P.; Akhlaghdoust M.; Alemayehu A.; Alvand S.; Alvis-Zakzuk N.J.; Amu H.; Antony B.; Arabloo J.; Aravkin A.Y.; Arulappan J.; Ashraf T.; Athari S.S.; Azadnajafabad S.; Badawi A.; Baghcheghi N.; Baig A.A.; Balta A.B.; Banach M.; Banik P.C.; Barrow A.; Bashiri A.; Bearne L.M.; Bekele A.; Bensenor I.M.; Berhie A.Y.; Bhagavathula A.S.; Bhardwaj P.; Bhat A.N.; Bhojaraja V.S.; Bitaraf S.; Bodicha B.B.A.; Botelho J.S.; Briggs A.M.; Buchbinder R.; Casta\u00f1eda-Orjuela C.A.; Charalampous P.; Chattu V.K.; Coberly K.; Cruz-Martins N.; Dadras O.; Dai X.; de Luca K.; Dessalegn F.N.; Dessie G.; Dhimal M.; Digesa L.E.; Diress M.; Doku P.N.; Edinur H.A.; Ekholuenetale M.; Elhadi M.; El-Sherbiny Y.M.; Etaee F.; Ezzeddini R.; Faghani S.; Filip I.; Fischer F.; Fukumoto T.; Ganesan B.; Gebremichael M.A.; Gerema U.; Getachew M.E.; Ghashghaee A.; Gill T.K.; Gupta B.; Gupta S.; Gupta V.B.; Gupta V.K.; Halwani R.; Hannan M.A.; Haque S.; Harlianto N.I.; Harorani M.; Hasaballah A.I.; Hassen M.B.; Hay S.I.; Hayat K.; Heidari G.; Hezam K.; Hill C.L.; Hiraike Y.; Horita N.; Hoveidaei A.H.; Hsiao A.K.; Hsieh E.; Hussain S.; Iavicoli I.; Ilic I.M.; Islam S.M.S.; Ismail N.E.; Iwagami M.; Jakovljevic M.; Jani C.T.; Jeganathan J.; Joseph N.; Kadashetti V.; Kandel H.; Kanko T.K.; Karaye I.M.; Khajuria H.; Khan M.J.; Khan M.A.B.; Khanali J.; Khatatbeh M.M.; Khubchandani J.; Kim Y.J.; Kisa A.; Kolahi A-A.; Kompani F.; Koohestani H.R.; Koyanagi A.; Krishan K.; Kuddus M.; Kumar N.; Kuttikkattu A.; Larijani B.; Lim S.S.; Lo J.; Machado V.S.; Mahajan P.B.; Majeed A.; Malakan Rad E.; Malik A.A.; Mansournia M.A.; Mathews E.; Mendes J.J.; Mentis A-F.A.; Mesregah M.K.; Mestrovic T.; Mirghaderi S.P.; Mirrakhimov E.M.; Misganaw A.; Mohamadkhani A.; Mohammed S.; Mokdad A.H.; Moniruzzaman M.; Montasir A.A.; Mulu G.B.; Murillo-Zamora E.; Murray C.J.L.; Mustafa G.; Naghavi M.; Nair T.S.; Naqvi A.A.; Natto Z.S.; Nayak B.P.; Neupane S.; Nguyen C.T.; Niazi R.K.; Nzoputam O.J.; Oh I-H.; Okati-Aliabad H.; Okonji O.C.; Olufadewa I.I.; Owolabi M.O.; Pacheco-Barrios K.; Padubidri J.R.; Patel J.; Pathan A.R.; Pawar S.; Pedersini P.; Perianayagam A.; Petcu I-R.; Qattea I.; Radfar A.; Rafiei A.; Rahman M.H.U.; Rahmanian V.; Rashedi V.; Rashidi M-M.; Ratan Z.A.; Rawaf S.; Razeghinia M.S.; Redwan E.M.M.; Renzaho A.M.N.; Rezaei N.; Rezaei N.; Riad A.; Saad A.M.A.; Saddik B.; Saeed U.; Safary A.; Sahebazzamani M.; Sahebkar A.; Sahoo H.; Salek Farrokhi A.; Saqib M.A.N.; Seylani A.; Shahabi S.; Shaikh M.A.; Shashamo B.B.; Shetty A.; Shetty J.K.; Shigematsu M.; Shivarov V.; Shobeiri P.; Sibhat M.M.; Sinaei E.; Singh A.; Singh J.A.; Singh P.; Singh S.; Siraj M.S.; Skryabina A.A.; Slater H.; Smith A.E.; Solomon Y.; Soltani-Zangbar M.S.; Tabish M.; Tan K-K.; Tat N.Y.; Tehrani-Banihashemi A.; Tharwat S.; Tovani-Palone M.R.; Tusa B.S.; Valadan Tahbaz S.; Valdez P.R.; Valizadeh R.; Vaziri S.; Vollset S.E.; Wu A-M.; Yada D.Y.; Yehualashet S.S.; Yonemoto N.; You Y.; Yunusa I.; Zangiabadian M.; Zare I.; Zarrintan A.; Zhang Z-J.; Zhong C.; Zoladl M.; Vos T.; March L.M.; Global, regional, and national burden of rheumatoid arthritis, 1990\u20132020, and projections to 2050: A systematic analysis of the Global Burden of Disease Study 2021. Lancet Rheumatol  2023,5(10),e594-e610","journal-title":"Lancet Rheumatol"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"1878","DOI":"10.3390\/medicina59101878","volume":"59","author":"Pavlov-Dolijanovic S.","year":"2023","unstructured":"Pavlov-Dolijanovic S.; Bogojevic M.; Nozica-Radulovic T.; Radunovic G.; Mujovic N.; Elderly-onset rheumatoid arthritis: Characteristics and treatment options. Medicina  2023,59(10),1878","journal-title":"Medicina"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1080\/1744666X.2023.2247158","volume":"19","author":"Sonomoto K.","year":"2023","unstructured":"Sonomoto K.; Tanaka Y.; Malignancies and rheumatoid arthritis, csDMARDs, biological DMARDs, and JAK inhibitors: Challenge and outlook. Expert Rev Clin Immunol  2023,19(11),1325-1342","journal-title":"Expert Rev Clin Immunol"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1038\/s41584-023-01036-x","volume":"19","author":"Feldmann M.","year":"2023","unstructured":"Feldmann M.; Maini R.N.; Soriano E.R.; Strand V.; Takeuchi T.; 25 years of biologic DMARDs in rheumatology. Nat Rev Rheumatol  2023,19(12),761-766","journal-title":"Nat Rev Rheumatol"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/j.rdc.2021.07.009","volume":"47","author":"Onel K.","year":"2021","unstructured":"Onel K.; Rumsey D.G.; Shenoi S.; Juvenile idiopathic arthritis Treatment updates. Rheum Dis Clin North Am  2021,47(4),545-563","journal-title":"Rheum Dis Clin North Am"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"e546","DOI":"10.1016\/S2665-9913(24)00097-3","volume":"6","author":"Giles I.","year":"2024","unstructured":"Giles I.; Thorne I.; Schmidt N.S.; Reid C.; Crossley A.; Panca M.; Freemantle N.; Tower C.; Dass S.; Sharma S.K.; Williams D.; O\u2019Neill S.; Dolhain R.J.E.M.; Toplak N.; Hodson K.; Nelson-Piercy C.; Clowse M.E.B.; The time of equipoise on the use of biological DMARDs in for inflammatory arthritis during pregnancy is finally over: A reappraisal of evidence to optimise pregnancy management. Lancet Rheumatol  2024,6(8),e546-e559","journal-title":"Lancet Rheumatol"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1056\/NEJMoa2209856","volume":"388","author":"Tuttle J.","year":"2023","unstructured":"Tuttle J.; Drescher E.; Sim\u00f3n-Campos J.A.; Emery P.; Greenwald M.; Kivitz A.; Rha H.; Yachi P.; Kiley C.; Nirula A.; A phase 2 trial of peresolimab for adults with rheumatoid arthritis. N Engl J Med  2023,388(20),1853-1862","journal-title":"N Engl J Med"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.1093\/rheumatology\/keac629","volume":"62","author":"Koike T.","year":"2023","unstructured":"Koike T.; Which should be first: Biologic DMARDs or janus kinase inhibitors? Rheumatology  2023,62(5),1738-1739","journal-title":"Rheumatology"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"e069681","DOI":"10.1136\/bmjopen-2022-069681","volume":"13","author":"Li Y.","year":"2023","unstructured":"Li Y.; Lau L.K.W.; Peng K.; Zhang D.; Dong D.; Wong I.C.K.; Li X.; Factors influencing choice of b\/ts DMARDs in managing inflammatory arthritis from a patient perspective: A systematic review of global evidence and a patient-based survey from hong kong. BMJ Open  2023,13(10),e069681","journal-title":"BMJ Open"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"105618","DOI":"10.1016\/j.phrs.2021.105618","volume":"169","author":"Kour G.","year":"2021","unstructured":"Kour G.; Haq S.A.; Bajaj B.K.; Gupta P.N.; Ahmed Z.; Phytochemical add-on therapy to DMARDs therapy in rheumatoid arthritis: in vitro and in vivo bases, clinical evidence and future trends. Pharmacol Res  2021,169,105618","journal-title":"Pharmacol Res"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1136\/ard-2022-223365","volume":"82","author":"Kerschbaumer A.","year":"2023","unstructured":"Kerschbaumer A.; Sepriano A.; Bergstra S.A.; Smolen J.S.; van der Heijde D.; Caporali R.; Edwards C.J.; Verschueren P.; de Souza S.; Pope J.E.; Takeuchi T.; Hyrich K.L.; Winthrop K.L.; Aletaha D.; Stamm T.A.; Schoones J.W.; Landew\u00e9 R.B.M.; Efficacy of synthetic and biological DMARDs: A systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis  2023,82(1),95-106","journal-title":"Ann Rheum Dis"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"638444","DOI":"10.3389\/fimmu.2021.638444","volume":"12","author":"Lu X.","year":"2021","unstructured":"Lu X.; Hu R.; Peng L.; Liu M.; Sun Z.; Efficacy and safety of adalimumab biosimilars: Current critical clinical data in rheumatoid arthritis. Front Immunol  2021,12,638444","journal-title":"Front Immunol"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1136\/annrheumdis-2019-216656","volume":"79","author":"Kerschbaumer A.","year":"2020","unstructured":"Kerschbaumer A.; Sepriano A.; Smolen J.S.; van der Heijde D.; Dougados M.; van Vollenhoven R.; McInnes I.B.; Bijlsma J.W.J.; Burmester G.R.; de Wit M.; Falzon L.; Landew\u00e9 R.; Efficacy of pharmacological treatment in rheumatoid arthritis: a systematic literature research informing the 2019 update of the EULAR recommendations for management of rheumatoid arthritis. Ann Rheum Dis  2020,79(6),744-759","journal-title":"Ann Rheum Dis"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1016\/j.pop.2010.07.001","volume":"37","author":"Birch J.T.","year":"2010","unstructured":"Birch J.T.; Bhattacharya S.; Emerging trends in diagnosis and treatment of rheumatoid arthritis. Prim Care  2010,37(4),779-792, vii","journal-title":"Prim Care"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1136\/ard-2023-224670","volume":"83","author":"Aymon R.","year":"2024","unstructured":"Aymon R.; Mongin D.; Bergstra S.A.; Choquette D.; Codreanu C.; De Cock D.; Dreyer L.; Elkayam O.; Huschek D.; Hyrich K.L.; Iannone F.; Inanc N.; Kearsley-Fleet L.; Koca S.S.; Kvien T.K.; Leeb B.F.; Lukina G.; Nordstr\u00f6m D.C.; Pavelka K.; Pombo-Suarez M.; Rodrigues A.; Rotar Z.; Strangfeld A.; Verschueren P.; Westermann R.; Zavada J.; Courvoisier D.S.; Finckh A.; Lauper K.; Evaluation of discontinuation for adverse events of JAK inhibitors and bDMARDs in an international collaboration of rheumatoid arthritis registers (the \u2018JAK-pot\u2019 study). Ann Rheum Dis  2024,83(4),421-428","journal-title":"Ann Rheum Dis"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"S82","DOI":"10.7326\/M24-0678","volume":"177","author":"Jalali K.","year":"2024","unstructured":"Jalali K.; Mandl L.A.; Rheumatology: What you may have missed in 2023. Ann Intern Med  2024,177(5_Supplement),S82-S90","journal-title":"Ann Intern Med"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"102234","DOI":"10.1016\/j.coph.2022.102234","volume":"64","author":"Conran C.A.","year":"2022","unstructured":"Conran C.A.; Moreland L.W.; A review of biosimilars for rheumatoid arthritis. Curr Opin Pharmacol  2022,64,102234","journal-title":"Curr Opin Pharmacol"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"107059","DOI":"10.1016\/j.phrs.2024.107059","volume":"200","author":"Roskoski R.","year":"2024","unstructured":"Roskoski R.; Properties of FDA-approved small molecule protein kinase inhibitors: A 2024 update. Pharmacol Res  2024,200,107059","journal-title":"Pharmacol Res"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"1037983","DOI":"10.3389\/fphar.2022.1037983","volume":"13","author":"Vugler A.","year":"2022","unstructured":"Vugler A.; O\u2019Connell J.; Nguyen M.A.; Weitz D.; Leeuw T.; Hickford E.; Verbitsky A.; Ying X.; Rehberg M.; Carrington B.; Merriman M.; Moss A.; Nicholas J.M.; Stanley P.; Wright S.; Bourne T.; Foricher Y.; Zhu Z.; Brookings D.; Horsley H.; Heer J.; Schio L.; Herrmann M.; Rao S.; Kohlmann M.; Florian P.; An orally available small molecule that targets soluble TNF to deliver anti-TNF biologic-like efficacy in rheumatoid arthritis. Front Pharmacol  2022,13,1037983","journal-title":"Front Pharmacol"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"1876","DOI":"10.3390\/cells9081876","volume":"9","author":"Massalska M.","year":"2020","unstructured":"Massalska M.; Maslinski W.; Ciechomska M.; Small molecule inhibitors in the treatment of rheumatoid arthritis and beyond: Latest updates and potential strategy for fighting COVID-19. Cells  2020,9(8),1876","journal-title":"Cells"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"519","DOI":"10.2147\/JIR.S219586","volume":"13","author":"Harrington R.","year":"2020","unstructured":"Harrington R.; Al Nokhatha S.A.; Conway R.; JAK inhibitors in rheumatoid arthritis: An evidence-based review on the emerging clinical data. J Inflamm Res  2020,13(13),519-531","journal-title":"J Inflamm Res"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"103276","DOI":"10.1016\/j.autrev.2023.103276","volume":"22","author":"Benucci M.","year":"2023","unstructured":"Benucci M.; Bernardini P.; Coccia C.; De Luca R.; Levani J.; Economou A.; Damiani A.; Russo E.; Amedei A.; Guiducci S.; Bartoloni E.; Manfredi M.; Grossi V.; Infantino M.; Perricone C.; JAK inhibitors and autoimmune rheumatic diseases. Autoimmun Rev  2023,22(4),103276","journal-title":"Autoimmun Rev"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1038\/s41392-023-01331-9","volume":"8","author":"Ding Q.","year":"2023","unstructured":"Ding Q.; Hu W.; Wang R.; Yang Q.; Zhu M.; Li M.; Cai J.; Rose P.; Mao J.; Zhu Y.Z.; Signaling pathways in rheumatoid arthritis: Implications for targeted therapy. Signal Transduct Target Ther  2023,8(1),68","journal-title":"Signal Transduct Target Ther"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1097\/BOR.0000000000000708","volume":"32","author":"Greenblatt H.K.","year":"2020","unstructured":"Greenblatt H.K.; Kim H.A.; Bettner L.F.; Deane K.D.; Preclinical rheumatoid arthritis and rheumatoid arthritis prevention. Curr Opin Rheumatol  2020,32(3),289-296","journal-title":"Curr Opin Rheumatol"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1007\/s10067-022-06399-2","volume":"42","author":"Fan D.","year":"2023","unstructured":"Fan D.; Tan P.; Jin L.; Qu Y.; Yu Q.; Bioinformatic identification and validation of autophagy-related genes in rheumatoid arthritis. Clin Rheumatol  2023,42(3),741-750","journal-title":"Clin Rheumatol"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"1192153","DOI":"10.3389\/fmed.2023.1192153","volume":"10","author":"Li X.","year":"2023","unstructured":"Li X.; He A.; Liu Y.; Huang Y.; Zhang X.; Bioinformatics identification of ferroptosis-related genes and therapeutic drugs in rheumatoid arthritis. Front Med  2023,10,1192153","journal-title":"Front Med"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1002\/art.41899","volume":"74","author":"Mc Ardle A.","year":"2022","unstructured":"Mc Ardle A.; Kwasnik A.; Szentpetery A.; Hernandez B.; Parnell A.; de Jager W.; de Roock S.; FitzGerald O.; Pennington S.R.; Identification and evaluation of serum protein biomarkers that differentiate psoriatic arthritis from rheumatoid arthritis. Arthritis Rheumatol  2022,74(1),81-91","journal-title":"Arthritis Rheumatol"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"3807","DOI":"10.18632\/aging.204714","volume":"15","author":"Guo Z.","year":"2023","unstructured":"Guo Z.; Ma Y.; Wang Y.; Xiang H.; Cui H.; Fan Z.; Zhu Y.; Xing D.; Chen B.; Tao H.; Guo Z.; Wu X.; Identification and validation of metabolism-related genes signature and immune infiltration landscape of rheumatoid arthritis based on machine learning. Aging  2023,15(9),3807-3825","journal-title":"Aging"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.ekir.2021.11.005","volume":"7","author":"Latt K.Z.","year":"2022","unstructured":"Latt K.Z.; Heymann J.; Jessee J.H.; Rosenberg A.Z.; Berthier C.C.; Arazi A.; Eddy S.; Yoshida T.; Zhao Y.; Chen V.; Nelson G.W.; Cam M.; Kumar P.; Mehta M.; Kelly M.C.; Kretzler M.; Ray P.E.; Moxey-Mims M.; Gorman G.H.; Lechner B.L.; Regunathan-Shenk R.; Raj D.S.; Susztak K.; Winkler C.A.; Kopp J.B.; Urine single-cell RNA sequencing in focal segmental glomerulosclerosis reveals inflammatory signatures. Kidney Int Rep  2022,7(2),289-304","journal-title":"Kidney Int Rep"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"112562","DOI":"10.1016\/j.intimp.2024.112562","volume":"138","author":"He Q.","year":"2024","unstructured":"He Q.; Sha X.; Ji J.; liu W.; Sun C.; Gu Z.; Identification of novel biomarker hsa_circ_0003914 for rheumatoid arthritis from plasma exosomes. Int Immunopharmacol  2024,138,112562","journal-title":"Int Immunopharmacol"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"3164","DOI":"10.1093\/rheumatology\/keae146","volume":"63","author":"C\u00eerciumaru A.","year":"2024","unstructured":"C\u00eerciumaru A.; Kisten Y.; Hansson M.; Mathsson-Alm L.; Joshua V.; W\u00e4h\u00e4maa H.; Loberg Haarhaus M.; Lindqvist J.; Padyukov L.; Catrina S.B.; Fei G.; Vivar N.; Rezaei H.; af Klint E.; Antovic A.; R\u00e9thi B.; Catrina A.I.; Hensvold A.; Identification of early risk factors for anti-citrullinated-protein-antibody positive rheumatoid arthritis\u2014A prospective cohort study. Rheumatology  2024,63(11),3164-3171","journal-title":"Rheumatology"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"23689","DOI":"10.18632\/aging.203641","volume":"13","author":"Chen Y.","year":"2021","unstructured":"Chen Y.; Ma C.; Liu L.; He J.; Zhu C.; Zheng F.; Dai W.; Hong X.; Liu D.; Tang D.; Dai Y.; Analysis of gut microbiota and metabolites in patients with rheumatoid arthritis and identification of potential biomarkers. Aging  2021,13(20),23689-23701","journal-title":"Aging"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"109095","DOI":"10.1016\/j.intimp.2022.109095","volume":"111","author":"Hu L.","year":"2022","unstructured":"Hu L.; Liu R.; Zhang L.; Advance in bone destruction participated by JAK\/STAT in rheumatoid arthritis and therapeutic effect of JAK\/STAT inhibitors. Int Immunopharmacol  2022,111,109095","journal-title":"Int Immunopharmacol"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"100223","DOI":"10.1016\/j.mtbio.2022.100223","volume":"14","author":"Zhang M.","year":"2022","unstructured":"Zhang M.; Hu W.; Cai C.; Wu Y.; Li J.; Dong S.; Advanced application of stimuli-responsive drug delivery system for inflammatory arthritis treatment. Mater Today Bio  2022,14,100223","journal-title":"Mater Today Bio"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"269","DOI":"10.4155\/tde-2020-0029","volume":"11","author":"Gorantla S.","year":"2020","unstructured":"Gorantla S.; Singhvi G.; Rapalli V.K.; Waghule T.; Dubey S.K.; Saha R.N.; Targeted drug-delivery systems in the treatment of rheumatoid arthritis: Recent advancement and clinical status. Ther Deliv  2020,11(4),269-284","journal-title":"Ther Deliv"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"3479","DOI":"10.1039\/D2NA00229A","volume":"4","author":"Nasra S.","year":"2022","unstructured":"Nasra S.; Bhatia D.; Kumar A.; Recent advances in nanoparticle-based drug delivery systems for rheumatoid arthritis treatment. Nanoscale Adv  2022,4(17),3479-3494","journal-title":"Nanoscale Adv"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"j3248","DOI":"10.1136\/bmj.j3248","volume":"358","author":"Ledingham J.","year":"2017","unstructured":"Ledingham J.; Snowden N.; Ide Z.; Diagnosis and early management of inflammatory arthritis. BMJ  2017,358,j3248","journal-title":"BMJ"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"8101","DOI":"10.1039\/D3FO01060K","volume":"14","author":"Kumar V.","year":"2023","unstructured":"Kumar V.; Mangla B.; Javed S.; Ahsan W.; Kumar P.; Garg V.; Dureja H.; Bromelain: A review of its mechanisms, pharmacological effects and potential applications. Food Funct  2023,14(18),8101-8128","journal-title":"Food Funct"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"54","DOI":"10.3390\/ph17010054","volume":"17","author":"Faustino C.","year":"2023","unstructured":"Faustino C.; Duarte N.; Pinheiro L.; Triterpenes drug delivery systems, a modern approach for arthritis targeted therapy. Pharmaceuticals  2023,17(1),54","journal-title":"Pharmaceuticals"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1039\/D4NR03611E","volume":"17","author":"Priya S.","year":"2024","unstructured":"Priya S.; Jain K.K.; Daryani J.; Desai V.M.; Kathuria H.; Singhvi G.; Revolutionizing rheumatoid arthritis treatment with emerging cutaneous drug delivery systems: Overcoming the challenges and paving the way forward. Nanoscale  2024,17(1),65-87","journal-title":"Nanoscale"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/j.jconrel.2020.09.016","volume":"327","author":"Qindeel M.","year":"2020","unstructured":"Qindeel M.; Ullah M.H.; Fakhar-ud-Din ; Ahmed N.; Rehman A.; Recent trends, challenges and future outlook of transdermal drug delivery systems for rheumatoid arthritis therapy. J Control Release  2020,327(327),595-615","journal-title":"J Control Release"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"115300","DOI":"10.1016\/j.addr.2024.115300","volume":"208","author":"Chapa-Villarreal F.A.","year":"2024","unstructured":"Chapa-Villarreal F.A.; Stephens M.; Pavlicin R.; Beussman M.; Peppas N.A.; Therapeutic delivery systems for rheumatoid arthritis based on hydrogel carriers. Adv Drug Deliv Rev  2024,208,115300","journal-title":"Adv Drug Deliv Rev"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"102273","DOI":"10.1016\/j.cis.2020.102273","volume":"285","author":"Saeedi T.","year":"2020","unstructured":"Saeedi T.; Alotaibi H.F.; Prokopovich P.; Polymer colloids as drug delivery systems for the treatment of arthritis. Adv Colloid Interface Sci  2020,285,102273","journal-title":"Adv Colloid Interface Sci"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"115325","DOI":"10.1016\/j.addr.2024.115325","volume":"209","author":"An X.","year":"2024","unstructured":"An X.; Yang J.; Cui X.; Zhao J.; Jiang C.; Tang M.; Dong Y.; Lin L.; Li H.; Wang F.; Advances in local drug delivery technologies for improved rheumatoid arthritis therapy. Adv Drug Deliv Rev  2024,209,115325","journal-title":"Adv Drug Deliv Rev"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1136\/ard-2023-224116","volume":"82","author":"\u00d8stergaard M.","year":"2023","unstructured":"\u00d8stergaard M.; van Vollenhoven R.F.; Rudin A.; Hetland M.L.; Heiberg M.S.; Nordstr\u00f6m D.C.; Nurmohamed M.T.; Gudbjornsson B.; \u00d8rnbjerg L.M.; B\u00f8yesen P.; Lend K.; H\u00f8rslev-Petersen K.; Uhlig T.; Sokka T.; Grondal G.; Krabbe S.; Lindqvist J.; Gjertsson I.; Glinatsi D.; Kapetanovic M.C.; Aga A.B.; Faustini F.; Parmanne P.; Lorenzen T.; Giovanni C.; Back J.; Hendricks O.; Vedder D.; Rannio T.; Grenholm E.; Ljos\u00e5 M.K.; Brodin E.; Lindegaard H.; S\u00f6derbergh A.; Rizk M.; Kastbom A.; Larsson P.; Uhrenholt L.; Just S.A.; Stevens D.J.; Bay Laurbjerg T.; Bakland G.; Olsen I.C.; Haavardsholm E.A.; Lampa J.; Bengtsson A.; G\u00fclfe A.; Blanken A.; Schlemmer A.; Kononoff A.; Turesson C.; Dackhammar C.; Gentline C.; Lindqvist E.; Hauge E-M.; Hermansson E.; Grenholm E.; Klint E.; R\u00f8devand E.; Baecklund E.; Markros F.; Rezaei H.; Relas H.; Valleala H.; Qirjazo I.; Hansen I.M.J.; Rutanen J.; Pedersen J.K.; Rathmann J.; Wallman J.; Carlestam J.; Einarsson J.; Lysholm J.; \u00d6berg K.; Almehed K.; Gr\u00f8n K.L.; Mykk\u00e4nen K.; Karlberg L.; Hemberg M.; Stilling-Vinther M.K.; Leirisalo-Repo M.; Hameed M.; Vivar N.; Kaipiainen-Sepp\u00e4nen O.; Olsson P.; Linge P.; Lindell P.; Jensen P.N.; \u00d8stg\u00e5rd R.; Tuompo R.; Dieperink S.; Christiansen S.N.; Exarchou S.; Saleh T.; Husmark T.; Olofsson T.; Ellingsen T.; Bruun T.; Certolizumab pegol, abatacept, tocilizumab or active conventional treatment in early rheumatoid arthritis: 48-week clinical and radiographic results of the investigator-initiated randomised controlled NORD-STAR trial. Ann Rheum Dis NORD-STAR study group 2023,82(10),1-10","journal-title":"Ann Rheum Dis"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"7759","DOI":"10.2147\/IJN.S435251","volume":"18","author":"Guo P.","year":"2023","unstructured":"Guo P.; Huang C.; Yang Q.; Zhong G.; Zhang J.; Qiu M.; Zeng R.; Gou K.; Zhang C.; Qu Y.; Advances in formulations of microneedle system for rheumatoid arthritis treatment. Int J Nanomedicine  2023,18(18),7759-7784","journal-title":"Int J Nanomedicine"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"2304333","DOI":"10.1002\/adma.202304333","volume":"36","author":"Shin M.J.","year":"2024","unstructured":"Shin M.J.; Park J.Y.; Park J.Y.; Lim S.H.; Lim H.; Choi J.K.; Park C.K.; Kang Y.J.; Khang D.; Inflammation-targeting mesenchymal stem cells combined with photothermal treatment attenuate severe joint inflammation. Adv Mater  2024,36(11),2304333","journal-title":"Adv Mater"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1007\/s13577-023-00873-y","volume":"36","author":"Yiou W.","year":"2023","unstructured":"Yiou W.; Zhihong W.; Shibai Z.; Shanni L.; Wenwei Q.; MiR-326 regulates cell proliferation and apoptosis in fibroblast-like synoviocytes in rheumatoid arthritis. Hum Cell  2023,36(3),987-996","journal-title":"Hum Cell"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"e003596","DOI":"10.1136\/rmdopen-2023-003596","volume":"10","author":"Zubrzycka-Sienkiewicz A.","year":"2024","unstructured":"Zubrzycka-Sienkiewicz A.; Klama K.; Ullmann M.; Petit-Frere C.; Baker P.; Monnet J.; Illes A.; Comparison of the efficacy and safety of a proposed biosimilar MSB11456 with tocilizumab reference product in subjects with moderate-to- severe rheumatoid arthritis: Results of a randomised double-blind study. RMD Open  2024,10(1),e003596","journal-title":"RMD Open"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"16","DOI":"10.3899\/jrheum.191252","volume":"48","author":"Fisher A.","year":"2021","unstructured":"Fisher A.; Hudson M.; Platt R.W.; Dormuth C.R.; Tofacitinib persistence in patients with rheumatoid arthritis: A retrospective cohort study. J Rheumatol  2021,48(1),16-24","journal-title":"J Rheumatol"},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1007\/s13346-023-01333-8","volume":"13","author":"Thumsi A.","year":"2023","unstructured":"Thumsi A.; Swaminathan S.J.; Mangal J.L.; Suresh A.P.; Acharya A.P.; Vaccines prevent reinduction of rheumatoid arthritis symptoms in collagen-induced arthritis mouse model. Drug Deliv Transl Res  2023,13(7),1925-1935","journal-title":"Drug Deliv Transl Res"},{"key":"ref=89","doi-asserted-by":"publisher","first-page":"2366","DOI":"10.1093\/rheumatology\/keac624","volume":"62","author":"Naveen R.","year":"2023","unstructured":"Naveen R.; Parodis I.; Joshi M.; Sen P.; Lindblom J.; Agarwal V.; Lilleker J.B.; Tan A.L.; Nune A.; Shinjo S.K.; Salim B.; Ziade N.; Velikova T.; Edgar Gracia-Ramos A.; Saavedra M.A.; Day J.; Makol A.; Distler O.; Chinoy H.; Agarwal V.; Aggarwal R.; Gupta L.; Nikiphorou E.; Barman B.; Singh Y.P.; Ranjan R.; Jain A.; Pandya S.C.; Pilania R.K.; Sharma A.; M M.; Gupta V.; Kavadichanda C.G.; Patro P.S.; Ajmani S.; Phatak S.; Goswami R.P.; Chowdhury A.C.; Mathew A.J.; Shenoy P.; Asranna A.; Bommakanti K.T.; Shukla A.; Pandey A.K.R.; Chandwar K.; Karde\u015f S.; Cansu D.\u00dc.; Kim M.; Makol A.; Chatterjee T.; Pauling J.D.; Wincup C.; Cavagna L.; Del Papa N.; Sambataro G.; Fabiola A.; Govoni M.; Parisi S.; Bocci E.B.; Sebastiani G.D.; Fusaro E.; Sebastiani M.; Quartuccio L.; Franceschini F.; Sainaghi P.P.; Orsolini G.; De Angelis R.; Danielli M.G.; Venerito V.; Milchert D.M.; Traboco L.S.; Wibowo S.A.K.; Tehozol E.A.Z.; Serrano J.R.; De La Torre I.G.; Loarce-Martos J.; Prieto-Gonz\u00e1lez S.; Gil-Vila A.; Gonzalez R.A.; Kuwana M.; Yoshida A.; Nakashima R.; Sato S.; Kimura N.; Kaneko Y.; Knitza J.; Tomaras S.; Gromova M.A.; Aharonov O.; Gheita T.A.; Hmamouchi I.; Hoff L.S.; Giannini M.; Maurier F.; Campagne J.; Meyer A.; Nagy-Vincze M.; Langguth D.; Limaye V.; Needham M.; Srivastav N.; Hudson M.; Landon-Cardinal O.; Shaharir S.S.; Zuleta W.G.R.; Silva J.A.P.; Fonseca J.E.; Zimba O.; COVID-19 vaccination in autoimmune diseases (COVAD) study: Vaccine safety and tolerance in rheumatoid arthritis. Rheumatology  2023,62(7),2366-2376","journal-title":"Rheumatology"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"183","DOI":"10.18502\/ijaai.v22i2.12679","volume":"22","author":"Rahimi-Khorashad M.","year":"2023","unstructured":"Rahimi-Khorashad M.; Ghoryani M.; Shabgah A.G.; Shariati-Sarabi Z.; Tavakkol-Afshari J.; Mohammadi M.; The effects of mesenchymal stem cells on the gene expression of TGF-beta and IFN-gamma in patients with rheumatoid arthritis. Iran J Allergy Asthma Immunol  2023,22(2),183-189","journal-title":"Iran J Allergy Asthma Immunol"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.jconrel.2023.02.035","volume":"356","author":"Han Y.","year":"2023","unstructured":"Han Y.; Huang S.; Nanomedicine is more than a supporting role in rheumatoid arthritis therapy. J Control Release  2023,356,142-161","journal-title":"J Control Release"},{"key":"ref=92","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1111\/imm.13855","volume":"173","author":"Lambuk F.","year":"2024","unstructured":"Lambuk F.; Nordin N.A.; Mussa A.; Lambuk L.; Ahmad S.; Hassan R.; Kadir R.; Mohamud R.; Yahya N.K.; Towards understanding the role of nanomedicine in targeting TNFR2 in rheumatoid arthritis. Immunology  2024,173(4),622-633","journal-title":"Immunology"},{"key":"ref=93","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1016\/j.apsb.2022.11.020","volume":"13","author":"Han Z.","year":"2023","unstructured":"Han Z.; Gao X.; Wang Y.; Cheng S.; Zhong X.; Xu Y.; Zhou X.; Zhang Z.; Liu Z.; Cheng L.; Ultrasmall iron-quercetin metal natural product nanocomplex with antioxidant and macrophage regulation in rheumatoid arthritis. Acta Pharm Sin B  2023,13(4),1726-1739","journal-title":"Acta Pharm Sin B"},{"key":"ref=94","doi-asserted-by":"publisher","first-page":"e2323098","DOI":"10.1001\/jamanetworkopen.2023.23098","volume":"6","author":"Bitoun S.","year":"2023","unstructured":"Bitoun S.; H\u00e4ssler S.; Ternant D.; Szely N.; Gleizes A.; Richez C.; Soubrier M.; Avouac J.; Brocq O.; Sellam J.; de Vries N.; Huizinga T.W.J.; Jury E.C.; Manson J.J.; Mauri C.; Matucci A.; Hacein Bey Abina S.; Mulleman D.; Pallardy M.; Bro\u00ebt P.; Mariette X.; Berenbaum F.; Dieud\u00e9 P.; Bertin P.; Dougados M.; Miceli C.; Pedriger A.; Marotte H.; Cantagrel A.; Vittecoq O.; Lequere T.; Saraux A.; Flipo R-M.; Sibilia J.; Gottenberg J.E.; Combe B.; Morel J.; Wendling D.; Verhoef C.; van Rijswijk M.; Nurmohamed M.; Vultaggio A.; Response to biologic drugs in patients with rheumatoid arthritis and antidrug antibodies. JAMA Netw Open  2023,6(7),e2323098","journal-title":"JAMA Netw Open"},{"key":"ref=95","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1021\/acs.molpharmaceut.0c00295","volume":"18","author":"Jeong M.","year":"2021","unstructured":"Jeong M.; Park J.H.; Nanomedicine for the treatment of rheumatoid arthritis. Mol Pharm  2021,18(2),539-549","journal-title":"Mol Pharm"},{"key":"ref=96","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1007\/s10787-022-01100-0","volume":"31","author":"Singh A.","year":"2023","unstructured":"Singh A.; Behl T.; Sehgal A.; Singh S.; Sharma N.; Naqwi M.; Mavi A.; Singh R.; Exploring the role of exosomes in rheumatoid arthritis. Inflammopharmacology  2023,31(1),119-128","journal-title":"Inflammopharmacology"},{"key":"ref=97","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/j.jconrel.2023.09.012","volume":"362","author":"Lu B.","year":"2023","unstructured":"Lu B.; Li C.; Jing L.; Zhuang F.; Xiang H.; Chen Y.; Huang B.; Rosmarinic acid nanomedicine for rheumatoid arthritis therapy: Targeted RONS scavenging and macrophage repolarization. J Control Release  2023,362,631-646","journal-title":"J Control Release"},{"key":"ref=98","doi-asserted-by":"publisher","first-page":"114388","DOI":"10.1016\/j.biopha.2023.114388","volume":"160","author":"Mena-V\u00e1zquez N.","year":"2023","unstructured":"Mena-V\u00e1zquez N.; Ruiz-Lim\u00f3n P.; Moreno-Indias I.; Manrique-Arija S.; Lisbona-Monta\u00f1ez J.M.; Rioja J.; Mucientes A.; Martin-N\u00fa\u00f1ez G.M.; Cano-Garc\u00eda L.; Tinahones F.J.; Fern\u00e1ndez-Nebro A.; Adiposity is associated with expansion of the genus dialister in rheumatoid arthritis patients. Biomed Pharmacother  2023,160,114388","journal-title":"Biomed Pharmacother"},{"key":"ref=99","doi-asserted-by":"publisher","first-page":"4417","DOI":"10.1016\/j.apsb.2023.05.025","volume":"13","author":"Xu Y.","year":"2023","unstructured":"Xu Y.; Zhao M.; Cao J.; Fang T.; Zhang J.; Zhen Y.; Wu F.; Yu X.; Liu Y.; Li J.; Wang D.; Applications and recent advances in transdermal drug delivery systems for the treatment of rheumatoid arthritis. Acta Pharm Sin B  2023,13(11),4417-4441","journal-title":"Acta Pharm Sin B"},{"key":"ref=100","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1080\/17425247.2022.2053674","volume":"19","author":"Gorantla S.","year":"2022","unstructured":"Gorantla S.; Batra U.; Samshritha RN ; Puppala E.R.; Waghule T.; Naidu V.G.M.; Singhvi G.; Emerging trends in microneedle-based drug delivery strategies for the treatment of rheumatoid arthritis. Expert Opin Drug Deliv  2022,19(4),395-407","journal-title":"Expert Opin Drug Deliv"},{"key":"ref=101","doi-asserted-by":"publisher","first-page":"451","DOI":"10.2174\/1567201820666230428124346","volume":"21","author":"Al-Nemrawi N.","year":"2024","unstructured":"Al-Nemrawi N.; Wahsheh Y.; Alzoubi K.H.; Transdermal delivery of methotrexate loaded in chitosan nanoparticles to treat rheumatoid arthritis. Curr Drug Deliv  2024,21(3),451-460","journal-title":"Curr Drug Deliv"},{"key":"ref=102","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1001\/jamadermatol.2023.4090","volume":"160","author":"Ingrassia J.P.","year":"2024","unstructured":"Ingrassia J.P.; Maqsood M.H.; Gelfand J.M.; Weber B.N.; Bangalore S.; Lo Sicco K.I.; Garshick M.S.; Cardiovascular and venous thromboembolic risk with JAK inhibitors in immune-mediated inflammatory skin diseases. JAMA Dermatol  2024,160(1),28-36","journal-title":"JAMA Dermatol"},{"key":"ref=103","doi-asserted-by":"publisher","first-page":"1934","DOI":"10.1080\/10717544.2022.2089295","volume":"29","author":"Zhang Y.","year":"2022","unstructured":"Zhang Y.; Gao Z.; Chao S.; Lu W.; Zhang P.; Transdermal delivery of inflammatory factors regulated drugs for rheumatoid arthritis. Drug Deliv  2022,29(1),1934-1950","journal-title":"Drug Deliv"},{"key":"ref=104","doi-asserted-by":"publisher","first-page":"103312","DOI":"10.1016\/j.autrev.2023.103312","volume":"22","author":"Konen F.F.","year":"2023","unstructured":"Konen F.F.; M\u00f6hn N.; Witte T.; Schefzyk M.; Wiestler M.; Lovric S.; Hufendiek K.; Schwenkenbecher P.; S\u00fchs K.W.; Friese M.A.; Klotz L.; Pul R.; Pawlitzki M.; Hagin D.; Kleinschnitz C.; Meuth S.G.; Skripuletz T.; Treatment of autoimmunity: The impact of disease-modifying therapies in multiple sclerosis and comorbid autoimmune disorders. Autoimmun Rev  2023,22(5),103312","journal-title":"Autoimmun Rev"},{"key":"ref=105","doi-asserted-by":"publisher","first-page":"363","DOI":"10.2147\/DDDT.S334727","volume":"16","author":"Ram\u00edrez-Mar\u00edn H.A.","year":"2022","unstructured":"Ram\u00edrez-Mar\u00edn H.A.; Tosti A.; Evaluating the therapeutic potential of ritlecitinib for the treatment of alopecia areata. Drug Des Devel Ther  2022,16(16),363-374","journal-title":"Drug Des Devel Ther"},{"key":"ref=106","doi-asserted-by":"publisher","first-page":"630","DOI":"10.3390\/biomedicines8120630","volume":"8","author":"Guimar\u00e3es D.","year":"2020","unstructured":"Guimar\u00e3es D.; Noro J.; Loureiro A.; Lager F.; Renault G.; Cavaco-Paulo A.; Nogueira E.; Increased encapsulation efficiency of methotrexate in liposomes for rheumatoid arthritis therapy. Biomedicines  2020,8(12),630","journal-title":"Biomedicines"},{"key":"ref=107","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.3390\/jpm13111550","volume":"13","author":"Assefi M.","year":"2023","unstructured":"Assefi M.; Lewandrowski K.U.; Lorio M.; Fiorelli R.K.A.; Landgraeber S.; Sharafshah A.; Network-based in silico analysis of new combinations of modern drug targets with methotrexate for response-based treatment of rheumatoid arthritis. J Pers Med  2023,13(11),1550","journal-title":"J Pers Med"},{"key":"ref=108","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1002\/art.41417","volume":"73","author":"Deane K.D.","year":"2021","unstructured":"Deane K.D.; Holers V.M.; Rheumatoid arthritis pathogenesis, prediction, and prevention: An emerging paradigm shift. Arthritis Rheumatol  2021,73(2),181-193","journal-title":"Arthritis Rheumatol"},{"key":"ref=109","doi-asserted-by":"publisher","first-page":"2267","DOI":"10.1007\/s10067-023-06654-0","volume":"42","author":"Conley B.","year":"2023","unstructured":"Conley B.; Bunzli S.; Bullen J.; O\u2019Brien P.; Persaud J.; Gunatillake T.; Nikpour M.; Grainger R.; Barnabe C.; Lin I.; What are the core recommendations for rheumatoid arthritis care? Systematic review of clinical practice guidelines. Clin Rheumatol  2023,42(9),2267-2278","journal-title":"Clin Rheumatol"},{"key":"ref=110","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1056\/NEJMoa2109927","volume":"386","author":"Ytterberg S.R.","year":"2022","unstructured":"Ytterberg S.R.; Bhatt D.L.; Mikuls T.R.; Koch G.G.; Fleischmann R.; Rivas J.L.; Germino R.; Menon S.; Sun Y.; Wang C.; Shapiro A.B.; Kanik K.S.; Connell C.A.; Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis. N Engl J Med  2022,386(4),316-326","journal-title":"N Engl J Med"},{"key":"ref=111","doi-asserted-by":"publisher","first-page":"6690","DOI":"10.3390\/jcm12206690","volume":"12","author":"Harrington R.","year":"2023","unstructured":"Harrington R.; Harkins P.; Conway R.; Janus kinase inhibitors in rheumatoid arthritis: An update on the efficacy and safety of tofacitinib, baricitinib and upadacitinib. J Clin Med  2023,12(20),6690","journal-title":"J Clin Med"},{"key":"ref=112","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1007\/s40264-020-01036-w","volume":"44","author":"Conaghan P.G.","year":"2021","unstructured":"Conaghan P.G.; Mysler E.; Tanaka Y.; Da Silva-Tillmann B.; Shaw T.; Liu J.; Ferguson R.; Enejosa J.V.; Cohen S.; Nash P.; Rigby W.; Burmester G.; Upadacitinib in rheumatoid arthritis: A benefit\u2013risk assessment across a phase III Program. Drug Saf  2021,44(5),515-530","journal-title":"Drug Saf"},{"key":"ref=113","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1002\/art.41589","volume":"73","author":"Curtis J.R.","year":"2021","unstructured":"Curtis J.R.; Emery P.; Karis E.; Haraoui B.; Bykerk V.; Yen P.K.; Kricorian G.; Chung J.B.; Etanercept or methotrexate withdrawal in rheumatoid arthritis patients in sustained remission. Arthritis Rheumatol  2021,73(5),759-768","journal-title":"Arthritis Rheumatol"},{"key":"ref=114","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1056\/NEJMoa2201302","volume":"387","author":"Smolen J.S.","year":"2022","unstructured":"Smolen J.S.; Feist E.; Fatenejad S.; Grishin S.A.; Korneva E.V.; Nasonov E.L.; Samsonov M.Y.; Fleischmann R.M.; Olokizumab versus placebo or adalimumab in rheumatoid arthritis. N Engl J Med  2022,387(8),715-726","journal-title":"N Engl J Med"},{"key":"ref=115","doi-asserted-by":"publisher","first-page":"985","DOI":"10.18553\/jmcp.2023.29.9.985","volume":"29","author":"Yin Y.","year":"2023","unstructured":"Yin Y.; McDermott C.; Lockhart C.; Real-world switching and discontinuation outcomes of infliximab biosimilars in patients with rheumatoid arthritis: A scoping review. J Manag Care Spec Pharm  2023,29(9),985-998","journal-title":"J Manag Care Spec Pharm"},{"key":"ref=116","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1080\/14397595.2020.1797266","volume":"31","author":"Shimizu H.","year":"2021","unstructured":"Shimizu H.; Kobayashi H.; Kanbori M.; Ishii Y.; Effectiveness of golimumab in rheumatoid arthritis patients with inadequate response to first-line biologic therapy: Results from a Japanese post- marketing surveillance study. Mod Rheumatol  2021,31(3),556-565","journal-title":"Mod Rheumatol"},{"key":"ref=117","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.3390\/jcm12041630","volume":"12","author":"Leone G.M.","year":"2023","unstructured":"Leone G.M.; Mangano K.; Petralia M.C.; Nicoletti F.; Fagone P.; Past, present and (Foreseeable) future of biological anti-TNF alpha therapy. J Clin Med  2023,12(4),1630","journal-title":"J Clin Med"},{"key":"ref=118","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1038\/s41591-022-01789-0","volume":"28","author":"Rivellese F.","year":"2022","unstructured":"Rivellese F.; Surace A.E.A.; Goldmann K.; Sciacca E.; \u00c7ubuk C.; Giorli G.; John C.R.; Nerviani A.; Fossati-Jimack L.; Thorborn G.; Ahmed M.; Prediletto E.; Church S.E.; Hudson B.M.; Warren S.E.; McKeigue P.M.; Humby F.; Bombardieri M.; Barnes M.R.; Lewis M.J.; Pitzalis C.; Rivellese F.; Giorli G.; Nerviani A.; Fossati-Jimack L.; Thorborn G.; Humby F.; Bombardieri M.; Lewis M.J.; Durez P.; Buch M.H.; Rizvi H.; Mahto A.; Montecucco C.; Lauwerys B.; Ng N.; Ho P.; Rom\u00e3o V.C.; da Fonseca J.E.C.; Verschueren P.; Kelly S.; Sainaghi P.P.; Gendi N.; Dasgupta B.; Cauli A.; Reynolds P.; Ca\u00f1ete J.D.; Ramirez J.; Celis R.; Moots R.; Taylor P.C.; Edwards C.J.; Isaacs J.; Sasieni P.; Choy E.; Thompson C.; Bugatti S.; Bellan M.; Congia M.; Holroyd C.; Pratt A.; White L.; Warren L.; Peel J.; Hands R.; Hadfield G.; Pitzalis C.; Rituximab versus tocilizumab in rheumatoid arthritis: Synovial biopsy-based biomarker analysis of the phase 4 R4RA randomized trial. Nat Med R4RA collaborative group 2022,28(6),1256-1268","journal-title":"Nat Med"},{"key":"ref=119","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1056\/NEJMoa2008250","volume":"383","author":"Rubbert-Roth A.","year":"2020","unstructured":"Rubbert-Roth A.; Enejosa J.; Pangan A.L.; Haraoui B.; Rischmueller M.; Khan N.; Zhang Y.; Martin N.; Xavier R.M.; Trial of upadacitinib or abatacept in rheumatoid arthritis. N Engl J Med  2020,383(16),1511-1521","journal-title":"N Engl J Med"},{"key":"ref=120","doi-asserted-by":"publisher","first-page":"2118","DOI":"10.3390\/jcm10102118","volume":"10","author":"Promelle V.","year":"2021","unstructured":"Promelle V.; Goeb V.; Gueudry J.; Rheumatoid arthritis associated episcleritis and scleritis: An update on treatment perspectives. J Clin Med  2021,10(10),2118","journal-title":"J Clin Med"},{"key":"ref=121","doi-asserted-by":"publisher","first-page":"2596","DOI":"10.1093\/rheumatology\/keab676","volume":"61","author":"Burmester G.R.","year":"2022","unstructured":"Burmester G.R.; Bykerk V.P.; Buch M.H.; Tanaka Y.; Kameda H.; Praestgaard A.; van Hoogstraten H.; Fernandez-Nebro A.; Huizinga T.; Sarilumab monotherapy vs sarilumab and methotrexate combination therapy in patients with rheumatoid arthritis. Rheumatology  2022,61(6),2596-2602","journal-title":"Rheumatology"},{"key":"ref=122","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1080\/09546634.2020.1755417","volume":"33","author":"Tegtmeyer K.","year":"2022","unstructured":"Tegtmeyer K.; Atassi G.; Zhao J.; Maloney N.J.; Lio P.A.; Off-Label studies on anakinra in dermatology: A review. J Dermatolog Treat  2022,33(1),73-86","journal-title":"J Dermatolog Treat"},{"key":"ref=123","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1016\/j.semarthrit.2021.08.007","volume":"51","author":"Cota-Arce J.M.","year":"2021","unstructured":"Cota-Arce J.M.; Cota J.; De Le\u00f3n-Nava M.A.; Hern\u00e1ndez-C\u00e1ceres A.; Moncayo-Salazar L.I.; Valle-Alvarado F.; Cordero-Moreno V.L.; Bonfil-Solis K.L.; Bichara-Figueroa J.E.; Hern\u00e1ndez-Hern\u00e1ndez J.; Villela L.; Efficacy and safety of canakinumab in the treatment of adult-onset still\u2019s disease: A systematic review. Semin Arthritis Rheum  2021,51(6),1282-1290","journal-title":"Semin Arthritis Rheum"},{"key":"ref=124","doi-asserted-by":"publisher","first-page":"102570","DOI":"10.1016\/j.jaccas.2024.102570","volume":"29","author":"Majid M.","year":"2024","unstructured":"Majid M.; Agrawal A.; Daniela Arockiam A.; Rosenzveig A.; Kumar A.; Singh Bhalla J.; Asghar M.S.; Shimshak T.; Brands C.; Klein A.L.; Unveiling rheumatoid arthritis. JACC Case Rep  2024,29(19),102570","journal-title":"JACC Case Rep"},{"key":"ref=125","doi-asserted-by":"publisher","first-page":"e43825","DOI":"10.7759\/cureus.43825","volume":"15","author":"Edupuganti S.","year":"2023","unstructured":"Edupuganti S.; Khine S.; Gupta R.; Yadav D.; Singh A.; Secukinumab-induced Crohn\u2019s disease in a patient treated for juvenile idiopathic arthritis. Cureus  2023,15(8),e43825","journal-title":"Cureus"},{"key":"ref=126","doi-asserted-by":"publisher","first-page":"3959","DOI":"10.1007\/s00204-020-02870-8","volume":"94","author":"Gr\u017eelj J.","year":"2020","unstructured":"Gr\u017eelj J.; Sollner Dolenc M.; The role of xenobiotics in triggering psoriasis. Arch Toxicol  2020,94(12),3959-3982","journal-title":"Arch Toxicol"},{"key":"ref=127","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1080\/1744666X.2023.2149495","volume":"19","author":"Westhovens R.","year":"2023","unstructured":"Westhovens R.; Filgotinib in rheumatoid arthritis. Expert Rev Clin Immunol  2023,19(2),135-144","journal-title":"Expert Rev Clin Immunol"},{"key":"ref=128","doi-asserted-by":"publisher","first-page":"193","DOI":"10.2185\/jrm.2022-005","volume":"17","author":"Nishimura A.","year":"2022","unstructured":"Nishimura A.; Tateiwa M.; Tajima S.; Tada T.; Efficacy of peficitinib in two patients with rheumatoid arthritis on maintenance hemodialysis. J Rural Med  2022,17(3),193-195","journal-title":"J Rural Med"},{"key":"ref=129","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1097\/BOR.0000000000000754","volume":"32","author":"Narain S.","year":"2020","unstructured":"Narain S.; Berman N.; Furie R.; Biologics in the treatment of Sjogren\u2019s syndrome, systemic lupus erythematosus, and lupus nephritis. Curr Opin Rheumatol  2020,32(6),609-616","journal-title":"Curr Opin Rheumatol"},{"key":"ref=130","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1007\/s00262-016-1792-y","volume":"65","author":"Becker P.S.A.","year":"2016","unstructured":"Becker P.S.A.; Suck G.; Nowakowska P.; Ullrich E.; Seifried E.; Bader P.; Tonn T.; Seidl C.; Selection and expansion of natural killer cells for NK cell-based immunotherapy. Cancer Immunol Immunother  2016,65(4),477-484","journal-title":"Cancer Immunol Immunother"},{"key":"ref=131","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1002\/jcp.26878","volume":"234","author":"Dianat-Moghadam H.","year":"2019","unstructured":"Dianat-Moghadam H.; Rokni M.; Marofi F.; Panahi Y.; Yousefi M.; Natural killer cell\u2013based immunotherapy: From transplantation toward targeting cancer stem cells. J Cell Physiol  2019,234(1),259-273","journal-title":"J Cell Physiol"},{"key":"ref=132","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1007\/s11684-018-0653-9","volume":"12","author":"Fang F.","year":"2018","unstructured":"Fang F.; Xiao W.; Tian Z.; Challenges of NK cell-based immunotherapy in the new era. Front Med  2018,12(4),440-450","journal-title":"Front Med"},{"key":"ref=133","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2018\/3057624","volume":"2018","author":"Wang M.","year":"2018","unstructured":"Wang M.; Yuan Q.; Xie L.; Mesenchymal stem cell-based immunomodulation: Properties and clinical application. Stem Cells Int  2018,2018,1-12","journal-title":"Stem Cells Int"},{"key":"ref=134","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1001\/jama.2018.18743","volume":"321","author":"Burt R.K.","year":"2019","unstructured":"Burt R.K.; Balabanov R.; Burman J.; Sharrack B.; Snowden J.A.; Oliveira M.C.; Fagius J.; Rose J.; Nelson F.; Barreira A.A.; Carlson K.; Han X.; Moraes D.; Morgan A.; Quigley K.; Yaung K.; Buckley R.; Alldredge C.; Clendenan A.; Calvario M.A.; Henry J.; Jovanovic B.; Helenowski I.B.; Effect of nonmyeloablative hematopoietic stem cell transplantation vs continued disease- modifying therapy on disease progression in patients with relapsing-remitting multiple sclerosis. JAMA  2019,321(2),165-174","journal-title":"JAMA"},{"key":"ref=135","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1158\/2326-6066.CIR-15-0190","volume":"3","author":"Houot R.","year":"2015","unstructured":"Houot R.; Schultz L.M.; Marabelle A.; Kohrt H.; T-cell\u2013based immunotherapy: Adoptive cell transfer and checkpoint inhibition. Cancer Immunol Res  2015,3(10),1115-1122","journal-title":"Cancer Immunol Res"},{"key":"ref=136","unstructured":"The use of synovial biopsies in predicting response to biologic therapy in rheumatoid arthritis patients (SYBRA). 2023. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05379322."},{"key":"ref=137","unstructured":"Intra-articular injection of MSC-derived exosomes in knee osteoarthritis (ExoOA-1) (ExoOA-1). 2021. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05060107."},{"key":"ref=138","doi-asserted-by":"publisher","first-page":"859927","DOI":"10.3389\/fbioe.2022.859927","volume":"10","author":"Huang Y.","year":"2022","unstructured":"Huang Y.; Li X.; Yang L.; Hydrogel encapsulation: taking the therapy of mesenchymal stem cells and their derived secretome to the next level. Front Bioeng Biotechnol  2022,10,859927","journal-title":"Front Bioeng Biotechnol"},{"key":"ref=139","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1186\/s13287-020-01920-3","volume":"11","author":"Lee B.C.","year":"2020","unstructured":"Lee B.C.; Kang K.S.; Functional enhancement strategies for immunomodulation of mesenchymal stem cells and their therapeutic application. Stem Cell Res Ther  2020,11(1),397","journal-title":"Stem Cell Res Ther"},{"key":"ref=140","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1111\/nyas.12815","volume":"1351","author":"Uccelli A.","year":"2015","unstructured":"Uccelli A.; de Rosbo N.K.; The immunomodulatory function of mesenchymal stem cells: Mode of action and pathways. Ann N Y Acad Sci  2015,1351(1),114-126","journal-title":"Ann N Y Acad Sci"},{"key":"ref=141","author":"Figueiredo M.D.","year":"2024","unstructured":"Figueiredo M.D.; Kyostio-Moore S.R.; Berthelette P.; Recombinant AAV vectors expressing osteoprotective genes, including HAS2 and lubricin, useful in the treatment of osteoarthritis and related joint conditions in mammals.  2024"},{"key":"ref=142","author":"Henderson J.A.","year":"2023","unstructured":"Henderson J.A.; Veits G.K.; He M.; Nasveschuk C.G.; Phillips A.J.; Good A.C.; Cereblon binders for the degradation of Ikaros.  2023"},{"key":"ref=143","author":"Noelle R.J.","year":"2021","unstructured":"Noelle R.J.; Ceeraz S.; LeMercier I.; Nowak E.; Lines J.; Novel VISTA-Ig constructs and the use of VISTA-Ig for treatment of autoimmune, allergic and inflammatory disorders.  2021"},{"key":"ref=144","author":"Jeong J.U.","year":"2021","unstructured":"Jeong J.U.; Bandyopadhyay D.; Eidam P.M.; Harris P.A.; Kang J.; King B.W.; Shah A.L.; Leister L.K.; Rahman A.; Ramanjulu J.M.; Sehon C.A.; Heterocyclic amides as kinase inhibitors.  2021"},{"key":"ref=145","author":"Konradi A.W.","year":"2021","unstructured":"Konradi A.W.; Galemmo R.A.; Lynch C.C.; Aminopyridine compounds and methods for the preparation and use thereof.  2021"},{"key":"ref=146","author":"Hu W.","year":"2020","unstructured":"Hu W.; Li J.; Li F.; Antibodies binding VISTA and uses thereof.  2020"},{"key":"ref=147","author":"Bacon E.M.","year":"2019","unstructured":"Bacon E.M.; Brizgys G.; Chin E.; Chou C.; Cottell J.J.; Link J.O.; Taylor J.G.; Winston C.T.; Wright N.E.; Yang Z.Y.; Zhang J.R.; Pyrrolo [1, 2-b] pyridazine derivatives.  2019"},{"key":"ref=148","author":"Lu Y.","year":"2020","unstructured":"Lu Y.; Lu J.F.; Angiopoietin 2, VEGF dual antagonists.  2020"},{"key":"ref=149","author":"Jeong J.U.","year":"2019","unstructured":"Jeong J.U.; Bandyopadhyay D.; Eidam P.M.; Harris P.A.; Kang J.; King B.W.; Shah A.L.; Leister L.K.; Rahman A.; Ramanjulu J.M.; Sehon C.A.; Heterocyclic amides as kinase inhibitors.  2019"},{"key":"ref=150","author":"Jaspers S.R.","year":"2018","unstructured":"Jaspers S.R.; Presnell S.R.; Methods of treating inflammation using IL-17A and IL-17F cross-reactive monoclonal antibodies.  2018"},{"key":"ref=151","author":"Wu C.","year":"2022","unstructured":"Wu C.; Fabs-in-tandem immunoglobulin and uses thereof.  2022"},{"key":"ref=152","author":"Ghivizzani S.C.","year":"2022","unstructured":"Ghivizzani S.C.; Compositions for treating conditions using recombinant self-complementary adeno-associated virus.  2022"},{"key":"ref=153","author":"Miossec P.","year":"2023","unstructured":"Miossec P.; Thiam N.; Pin J.J.; Anti-IL17A autoantibodies for treating or reducing the likelihood of occurrence of bone destruction associated with a chronic autoimmune or inflammatory disease.  2023"},{"key":"ref=154","author":"Lopez-Girona A.","year":"2018","unstructured":"Lopez-Girona A.; Schafer P.H.; Gandhi A.; Mendy D.; Daniel T.O.; Methods for the treatment of cancer and inflammatory diseases using cereblon as a predictor.  2018"},{"key":"ref=155","author":"McFadden D.G.","year":"2023","unstructured":"McFadden D.G.; Lewin A.S.; Lucas A.R.; Ildefonso C.J.; Rahman M.M.; Use of AAV-expressed M013 protein as an anti-inflammatory therapeutic.  2023"},{"key":"ref=156","author":"Jaspers S.R.","year":"2018","unstructured":"Jaspers S.R.; Presnell S.R.; Huber M.J.; Monoclonal antibodies that bind both IL-17A and IL-17F.  2018"},{"key":"ref=157","author":"Wong J.","year":"2018","unstructured":"Wong J.; Vasquez M.; Antibodies that bind colony stimulating factor 1 receptor (CSF1R).  2018"},{"key":"ref=158","author":"Wu C.","year":"2019","unstructured":"Wu C.; Epimab Biotherapeutics Inc, assignee. Fabs-in-tandem immunoglobulin and uses thereof. .  2019"},{"key":"ref=159","author":"Green L.L.","year":"2018","unstructured":"Green L.L.; Zhou Q.; Keyt B.A.; Yang X.D.; Emery S.C.; Blakey D.C.; Antibodies directed to angiopoietin-2 and uses thereof.  2018"},{"key":"ref=160","author":"Stevens BL","year":"2020","unstructured":"Stevens BL; Witte A; Rixon MW; Cardarelli JM; Kempe TD; Presnell SR; Srinivasan M; Chen G; Hui WE; Krystek SR; Il-17a\/f il-23 bispecific antibodies and their uses.  2020"},{"key":"ref=161","author":"Noelle RJ","year":"2023","unstructured":"Noelle RJ; Ceeraz S; LeMercier I; Nowak E; Lines JL; Novel vista-ig constructs and the use of vista-ig for treatment of autoimmune, allergic and inflammatory disorders.  2023"},{"key":"ref=162","author":"Fangbin H.A.","year":"2018","unstructured":"Fangbin H.A.; Lei H.; Lin X.; Meng Q.; Wang Y.; Modulators of the retinoid-related orphan receptor gamma (ROR-gamma) for use in the treatment of autoimmune and inflammatory diseases.  2018"},{"key":"ref=163","author":"Huang X.","year":"2021","unstructured":"Huang X.; Jasson M.; Marks V.; Radin A.; Compositions for the treatment of rheumatoid arthritis and methods of using same.  2021"},{"key":"ref=164","unstructured":"Effect of proactive therapeutic drug monitoring on maintenance of sustained disease control in adults with rheumatoid arthritis on a subcutaneous TNF inhibitor: The rheumatoid arthritis therapeutic drug monitoring trial (RA-DRUM) (RA-DRUM). 2025. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06440629."},{"key":"ref=165","unstructured":"Paroxetine safety and efficacy in rheumatoid arthritis. 2025. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06231745"},{"key":"ref=166","unstructured":"A clinical study of TQH3821 tablets in the treatment of treated rheumatoid arthritis. 2025. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05849727"},{"key":"ref=167","unstructured":"A phase 1b study of imvotamab in moderate to severe rheumatoid arthritis. 2025. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06087406"},{"key":"ref=168","unstructured":"The effects of mesenchymal stem cell secretome in rheumatoid arthritis patients. 2025. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05925647"},{"key":"ref=169","unstructured":"Role of nitazoxanide and escitalopram in patients with rheumatoid arthritis. 2025. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05480878"},{"key":"ref=170","unstructured":"Trivalent chromium treatment for rheumatoid arthritis. 2025. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05545020"},{"key":"ref=171","unstructured":"Advanced therapeutics in rheumatoid arthritis (RA). 2025. Available from: https:\/\/clinicaltrials.gov\/study\/NCT03976245"},{"key":"ref=172","unstructured":"Combination of baricitinib and anti-TNF in rheumatoid arthritis (CRI-RA). 2025. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04870203"},{"key":"ref=173","unstructured":"Methotrexate and metformin in rheumatoid arthritis patients (METorMET\u00b2). 2025. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04196868"},{"key":"ref=174","unstructured":"Adalimumab drug optimisation in rheumatoid arthritis using therapeutic drug monitoring (ADDORA). 2025. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04194827"},{"key":"ref=175","unstructured":"Efficacy and safety of TwHF and MTX in patients with rheumatoid arthritis. 2025. Available from: https:\/\/clinicaltrials.gov\/study\/NCT03324412"},{"key":"ref=176","unstructured":"Musculoskeletal ultrasound assessment of therapeutic response of tofacitinib in rheumatoid arthritis patients. 2025. Available from: https:\/\/clinicaltrials.gov\/study\/NCT02321930"},{"key":"ref=177","unstructured":"Clinical trial to compare treatment with GP2017 and Humira\u00ae in patients with rheumatoid arthritis (ADMYRA). 2025. Available from: https:\/\/clinicaltrials.gov\/study\/NCT02744755"},{"key":"ref=178","unstructured":"Repository corticotropin injection to treat rheumatoid arthritis patients who have failed three biologic therapies. 2025. Available from: https:\/\/clinicaltrials.gov\/study\/NCT01966718"},{"key":"ref=179","unstructured":"A study on the safety of administering rituximab at a more rapid rate in patients with rheumatoid arthritis (RATE-RA). 2025. Available from: https:\/\/clinicaltrials.gov\/study\/NCT01382940"},{"key":"ref=180","unstructured":"Exposure study comparing 3 routes of methotrexate (MTX) administration. 2025. Available from: https:\/\/clinicaltrials.gov\/study\/NCT01737944"},{"key":"ref=181","unstructured":"Long-term treatment study of certolizumab pegol without coadministration of methotrexate in japanese rheumatoid arthritis (RA) patients. 2025. Available from: https:\/\/clinicaltrials.gov\/study\/NCT00850343"},{"key":"ref=182","unstructured":"Long-term treatment study of certolizumab pegol (CDP870) as add-on medication to methotrexate in japanese rheumatoid arthritis (RA) patients. 2025. Available from: https:\/\/clinicaltrials.gov\/study\/NCT00851318"},{"key":"ref=183","unstructured":"PoC in rheumatoid arthritis with methotrexate. 2025. Available from: https:\/\/clinicaltrials.gov\/study\/NCT00605735"},{"key":"ref=184","unstructured":"Monoarticular corticosteroid injection versus systemic administration in the treatment of rheumatoid arthritis patients. 2025. Available from: https:\/\/clinicaltrials.gov\/study\/NCT00506896"},{"key":"ref=185","unstructured":"Long-term treatment study of mra for rheumatoid arthritis (RA) from study MRA012JP. 2025. Available from: https:\/\/clinicaltrials.gov\/study\/NCT00144547"},{"key":"ref=186","unstructured":"Adalimumab administered in Korean rheumatoid arthritis subjects treated with methotrexate. 2025. Available from: https:\/\/clinicaltrials.gov\/study\/NCT00235859"},{"key":"ref=187","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/S2468-1253(21)00223-5","volume":"7","author":"Papamichael K.","year":"2022","unstructured":"Papamichael K.; Afif W.; Drobne D.; Dubinsky M.C.; Ferrante M.; Irving P.M.; Kamperidis N.; Kobayashi T.; Kotze P.G.; Lambert J.; Noor N.M.; Roblin X.; Roda G.; Vande Casteele N.; Yarur A.J.; Arebi N.; Danese S.; Paul S.; Sandborn W.J.; Vermeire S.; Cheifetz A.S.; Peyrin-Biroulet L.; Therapeutic drug monitoring of biologics in inflammatory bowel disease: unmet needs and future perspectives. Lancet Gastroenterol Hepatol International Consortium for Therapeutic Drug Monitoring 2022,7(2),171-185","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"ref=188","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1007\/s40744-022-00475-4","volume":"9","author":"Momtazmanesh S.","year":"2022","unstructured":"Momtazmanesh S.; Nowroozi A.; Rezaei N.; Artificial intelligence in rheumatoid arthritis: Current status and future perspectives: A state-of-the-art review. Rheumatol Ther  2022,9(5),1249-1304","journal-title":"Rheumatol Ther"},{"key":"ref=189","doi-asserted-by":"publisher","first-page":"107969","DOI":"10.1016\/j.pec.2023.107969","volume":"116","author":"Knudsen L.R.","year":"2023","unstructured":"Knudsen L.R.; Lomborg K.; Hauge E.M.; Zangi H.A.; de Thurah A.; The WebRA study: Opportunities and challenges in digital patient education from the perspective of patients with rheumatoid arthritis: A qualitative study. Patient Educ Couns  2023,116,107969","journal-title":"Patient Educ Couns"},{"key":"ref=190","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.3390\/jcm9041082","volume":"9","author":"Cassone G.","year":"2020","unstructured":"Cassone G.; Manfredi A.; Vacchi C.; Luppi F.; Coppi F.; Salvarani C.; Sebastiani M.; Treatment of rheumatoid arthritis-associated interstitial lung disease: Lights and shadows. J Clin Med  2020,9(4),1082","journal-title":"J Clin Med"},{"key":"ref=191","doi-asserted-by":"publisher","first-page":"105494","DOI":"10.1016\/j.phrs.2021.105494","volume":"170","author":"Kessler J.","year":"2021","unstructured":"Kessler J.; Totoson P.; Devaux S.; Moretto J.; Wendling D.; Demougeot C.; Animal models to study pathogenesis and treatments of cardiac disorders in rheumatoid arthritis: Advances and challenges for clinical translation. Pharmacol Res  2021,170,105494","journal-title":"Pharmacol Res"},{"key":"ref=192","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1001\/jama.2018.13103","volume":"320","author":"Aletaha D.","year":"2018","unstructured":"Aletaha D.; Smolen J.S.; Diagnosis and management of rheumatoid arthritis. JAMA  2018,320(13),1360-1372","journal-title":"JAMA"},{"key":"ref=193","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1186\/s12913-024-11597-6","volume":"24","author":"Knudsen L.R.","year":"2024","unstructured":"Knudsen L.R.; Lomborg K.; Hauge E.M.; de Thurah A.; Facilitators and challenges of implementing a digital patient education programme for rheumatoid arthritis into clinical practice. BMC Health Serv Res  2024,24(1),1104","journal-title":"BMC Health Serv Res"},{"key":"ref=194","doi-asserted-by":"publisher","first-page":"1490300","DOI":"10.3389\/fnins.2024.1490300","volume":"18","author":"Liu F.J.","year":"2024","unstructured":"Liu F.J.; Wu J.; Gong L.J.; Yang H.S.; Chen H.; Non-invasive vagus nerve stimulation in anti-inflammatory therapy: Mechanistic insights and future perspectives. Front Neurosci  2024,18,1490300","journal-title":"Front Neurosci"}],"container-title":["Current Drug Targets"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0113894501396008251028055819","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/250590\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0113894501396008251028055819","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T03:59:53Z","timestamp":1789703993000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/250590\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":194,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/0113894501396008251028055819","relation":{},"ISSN":["1389-4501"],"issn-type":[{"value":"1389-4501","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Double blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2025-02-26","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-06-18","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-06-20","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-08-31","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}